Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy

被引：0
|
作者：
Boughdad, Sarah [1 ]
Meyer, Marie [1 ]
Da Mota, Michael [1 ]
Allenbach, Gilles [2 ]
Nicod-Lalonde, Marie [1 ]
Prior, John [3 ]
Schaefer, Niklaus [1 ]
机构：
[1] CHU Vaudois, Lausanne, Switzerland
[2] CHUV, Epalinges, Switzerland
[3] Lausanne Univ Hosp, La Conversion, Switzerland
来源：
JOURNAL OF NUCLEAR MEDICINE | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
80
引用
收藏
页数：2
相关论文
共 50 条
  • [21] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [22] Safety and response to177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Liu, Qingxing
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [23] Transformation of PSMA-avid to FDG-avid disease in metastatic castration-resistant prostate cancer in the setting of biochemical response with LU177-PSMA-617
    Sidhu, A.
    Singh, P.
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2025, 17
  • [24] Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Dwabe, Sami
    Yazdanpanah, Omid
    Warnecke, Brian
    Benjamin, David Joseph
    Rezazadeh, Arash
    Mar, Nataliya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Effectiveness of 177Lu PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Gunalp, Bengul
    Emer, Mustafa
    Ozaydin, Sukru
    Alagoz, Engin
    Ince, Semra
    Ayan, Asli
    Alkan, Sumeyye
    Mahmudov, Sarkhan
    Okuyucu, Kursat
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [26] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [27] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [28] Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
    Gadot, Moran
    Davidson, Tima
    Aharon, Margalit
    Atenafu, Eshetu G.
    Malki, Avraham
    Levartovsky, Meital
    Saad, Akram
    Domachevsky, Liran
    Berger, Raanan
    Leibowitz, Raya
    CANCERS, 2020, 12 (05)
  • [29] PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment.
    Li, Haoran
    Wulff-Burchfield, Elizabeth Marie
    Abbasi, Saqib
    Narang, Arshit
    Dal, Emre
    Donald, Joseph
    Yap, Wendell Y.
    Shen, Xinglei
    Chen, Ronald C.
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 157 - 157
  • [30] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
12345